Abstract
Objectives: In clinical trials elexacaftor/tezacaftor/ivacaftor (ETI) has shown significant improvement in clinically important parameters in children with CF (cwCF) including reduction in sweat chloride levels. In our study we aimed to check effect of ETI on sweat chloride levels in cwCF in real-world clinical practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
